Sun Pharmaceutical Industries Ltd.’s effort around specialty portfolio ramp up is yielding favorable progress as prescription trends around the key products suggest growth on a QoQ basis.

Levulan which was significantly below pre Covid-19 levels has broadly normalized, but we need to monitor the impact of resurgence in Covid cases.

We are in fact seeing faint signals of an unfavorable impact of the second Covid wave as trends seems to suggest weakening prescription volumes across product categories in the last week of November.

Source link

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *